rts logo

Here are the top Institutional holders of Alnylam Pharmaceuticals Inc (ALNY) shares

Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) is 34.66% higher on its value in year-to-date trading and has touched a low of $141.98 and a high of $256.24 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The ALNY stock was last observed hovering at around $254.74 in the last trading session, with the day’s gains setting it 3.02%.

Currently trading at $257.76, the stock is 25.05% and 49.64% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.93 million and changing 1.19% at the moment leaves the stock 53.55% off its SMA200. ALNY registered 33.78% gain for a year compared to 6-month loss of 30.96%.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

The stock witnessed a 68.71% gain in the last 1 month and extending the period to 3 months gives it a 65.34%, and is 4.10% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 1.94% over the week and 3.73% over the month.

Alnylam Pharmaceuticals Inc (ALNY) has around 2100 employees, a market worth around $32.60B and $2.00B in sales. Profit margin for the company is -16.58%. Distance from 52-week low is 81.55% and 0.59% from its 52-week high. The company has generated returns on investments over the last 12 months (-13.97%).

The EPS is expected to grow by 0.86% this year

The shares outstanding are 125.79M, and float is at 125.76M with Short Float at 1.69%.

Alnylam Pharmaceuticals Inc (ALNY) Insider Activity

The most recent transaction is an insider sale by SCHULMAN AMY W, the company’s Director. SEC filings show that SCHULMAN AMY W sold 8,500 shares of the company’s common stock on Jun 25 ’24 at a price of $240.00 per share for a total of $2.04 million. Following the sale, the insider now owns 8436.0 shares.

Alnylam Pharmaceuticals Inc disclosed in a document filed with the SEC on Jun 25 ’24 that Greenstreet Yvonne (Chief Executive Officer) sold a total of 8,301 shares of the company’s common stock. The trade occurred on Jun 25 ’24 and was made at $230.99 per share for $1.92 million. Following the transaction, the insider now directly holds 80534.0 shares of the ALNY stock.

Still, SEC filings show that on Jun 25 ’24, Garg Pushkal (CMO & EVP Dev & Med Affairs) disposed off 2,103 shares at an average price of $230.99 for $0.49 million. The insider now directly holds 15,609 shares of Alnylam Pharmaceuticals Inc (ALNY).

Related Posts